Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2012-05-18 12:59:18
Reporting Period:
Filing Date:
Filing Date Changed:
Accepted Time:
2012-05-18 13:59:18
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
827809 Qlt Inc QLTI Pharmaceutical Preparations (2834) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1360509 Florian Schonharting Ostergade 24A, 1
Copenhagen K G7
No No Yes No
1451330 K/s Equity Public Nb Ostergade 24A, 1
Copenhagen K G7
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares, No Par Value Acquisiton 2012-05-16 50,000 $6.67 7,447,626 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.70 inclusive. The Reporting Owners undertake to provide to QLT, Inc., any security holder of QLT, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
  2. Reported shares are owned directly by NB Public Equity K/S (the "Fund"), and indirectly by the other listed Reporting Owner.
  3. Florian Schonharting is a direct investor in a limited partner in the Fund and a director of Nordic Biotech Advisors ApS, which owns 100% of the shares of NB Public Equity Komplementar ApS, the general partner of the Fund. Mr. Schonharting disclaims beneficial ownership in the securities, except to the extent of his pecuniary interest therein.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!